Vésale Bioscience is a Belgian biotech, created in 2018 as a spin-out of Vésale Pharma thanks to its long experience in microbiotics.

We fight AntiMicrobial Resistant infections (AMR) with our personalized phage therapy solutions:
– We have developed a fast diagnostic tool Inteliphage®, an automated Phagogram, that will recommend the optimal phages association (2 or 3) to fight the patient’s bacteria.
– We produce a library of phages and deliver the selected phages as API for tailored magistral preparations. This approach dramatically increases the success rate of AMR treatments and has already been tested in more than 100 critically ill patients without major safety concerns. Our current phage library targets S.Aureus, K.Pneumoniae, E.Coli and P.Aeruginosa, responsible for 70% of AMR infections in EU & US.

Vésale Bioscience has a track record of successful partnerships with academic and clinical research organizations.

We have developed a broad scientific network, including the Queen Astrid Military Hospital (BE), Laboratory of Brussels University Hospitals (BE), Eliava Institute (Georgia), … and benefit from grants of the Walloon Region to develop innovative solutions for human and veterinary use.

Our success lies in our unique ability to identify novel phages across many indications, to purify, educate and produce them in the appropriate galenic to reach the targeted bacteria.

Vésale Bioscience is always interested in establishing new alliances and partnerships and welcome proposals in these areas.

We are also open to discussions with pharmaceutical companies the co-development of our innovative solutions outside of Europe or for veterinary use.

We are actively looking for commercial partners for our current assets. Many territories are still open for licensing/distribution agreements.

Contact for partnerships
Please submit your business development proposals via email to info@phage.health